-+ 0.00%
-+ 0.00%
-+ 0.00%

Editas Medicine Q3 2026 net loss attributable to common stockholders narrows 7% to $23.4 million

PUBT·11/09/2026 12:10:00
Listen to the news
Editas Medicine Q3 2026 net loss attributable to common stockholders narrows 7% to $23.4 million
  • Editas Medicine’s third-quarter 2026 net loss attributable to common stockholders narrowed 7% year over year to $23.4 million.
  • Collaboration and other research and development revenues climbed 39% year over year to $10.4 million, primarily from strategic-partner clinical development milestones.
  • Cash, cash equivalents and marketable securities totaled $190.2 million at September 30, supporting operations into the second half of 2028.
  • EDIT-401 patient dosing remains on track to begin in 2026, with initial safety and tolerability data expected in the first quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONEFULLFEED9872866) on November 09, 2026, and is solely responsible for the information contained therein.